Amgen Inc (AMGN) 132.53 $AMGN
Final Glance: Biotechnology companies
AP - Thu Aug 21, 5:08PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Thu Aug 21, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead Sciences, Amgen, Roche and Biogen
PR Newswire - Thu Aug 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Roche (OTC:RHHBY-Free Report) and Biogen (Nasdaq:BIIB-Free Report).
Lilly psoriasis drug fares well in late-stage test
AP - Thu Aug 21, 7:55AM CDT
INDIANAPOLIS (AP) — Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.
3 Reasons Gilead Science, Inc.’s Stock Could Rise
Brian Orelli, The Motley Fool - Motley Fool - Wed Aug 20, 4:36PM CDT
Gilead Sciences is trading near all-time highs, but there's still potential for the stock price to go even higher. Here are three things that could send shares higher if they come to fruition. Source: Gilead. 1. Sales of Gilead's...
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.
Early Glance: Biotechnology companies
AP - Wed Aug 20, 11:21AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.
Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck
PR Newswire - Wed Aug 20, 8:20AM CDT
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Medtronic, Inc. (NYSE: MDT) and Merck (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5855-100free.
Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk
M2 - Wed Aug 20, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6xznb6/global_hormone) has announced the addition of the "Global Hormone Replacement Therapy Market 2014-2018" report to their offering. Hormone replacement therapy, also known as hormone therapy, is a means of replacing hormones that are no longer being produced by the body. This type of therapy is usually initiated at menopause or may be started while a woman is in the perimenopausal phase, nearing menopause. Hormone replacement therapy replenishes the hormones required by the human body to function by using bio-identical hormones. The therapy contains estrogen and progesterone, and in some cases testosterone, to reduce symptoms of menopause. This replacement therapy may also protect against osteoporosis, reduce the risk of coronary heart disease, and may prevent or delay the onset of Alzheimer's disease. Replacement therapy can also increase the chance of developing more serious health complications such as blood clots, breast cancer, uterine cancer, and bowel cancer. The analysts forecast the Global Hormone Replacement Therapy market will grow at a CAGR of 2.51 percent over the period 2013-2018. The Global Hormone Replacement Therapy market can be divided into three segments: Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, and Thyroid Hormone Replacement Therapy. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Type of Therapy 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Actavis plc - Bayer AG - Merck & Co. Inc. - Novartis AG - Novo Nordisk A/S - Abbott Laboratories Ltd. - Amgen Inc. - ANI Pharmaceuticals Inc. - Hisamitsu Pharmaceutical Co. Inc. - MylanLaboratories Inc. - Orion Corp. - QuatRx Pharmaceuticals Co. - Teva Pharmaceutical Industries Ltd. - TherapeuticsMD Inc. For more information visit http://www.researchandmarkets.com/research/6x...al_hormone
Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 4:25PM CDT
Amgen Inc. (AMGN) announced that AMG 416 has met the primary as well as secondary endpoints in the second phase III registration study.
14.4% Return Seen to Date on SmarTrend Amgen Call (AMGN)
Comtex SmarTrend(R) - Tue Aug 19, 9:42AM CDT
SmarTrend identified an Uptrend for Amgen (NASDAQ:AMGN) on June 2nd, 2014 at $116.45. In approximately 3 months, Amgen has returned 14.41% as of today's recent price of $133.22.
A New Cannabinoid-based Arthritis Therapy in the Making
ACCESSWIRE - Tue Aug 19, 8:50AM CDT
WHITEFISH, MT / August 19, 2014 / Cannabinoids have been the focus of intense clinical research following the legalization of medical cannabis by several U.S. states. While pioneers like British-based GW Pharmaceuticals plc (NASDAQ: GWPH) have been actively studying cannabinoids since the 1990s, many North American companies haven't started major research until recent years with compounds just starting clinical trials.
Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company
PR Newswire - Tue Aug 19, 12:55AM CDT
Gamida Cell, a world leader in stem cell expansion technologies and therapeutic products, announced today that it has signed an investment and option agreement with Novartis Pharma AG ("Novartis"
. According to the agreement, Novartis will invest $35 million in Gamida Cell and in return will receive 15% equity and an option to fully acquire Gamida Cell. The option is exercisable for a limited period of time following achievement of certain milestones connected to the development of NiCord®, anticipated to be met during 2015. Completion of the transaction is subject to customary closing conditions.
3 Reasons Amgen, Inc.'s Stock Could Rise
Sean Williams, The Motley Fool - Motley Fool - Mon Aug 18, 5:13PM CDT
As you can see below, Amgen shareholders have had a great three years, with Amgen's stock having risen by more than 160%. AMGN data by YCharts The company's second-quarter earnings results, released three weeks ago, prove testament...
Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis
PR Newswire - Mon Aug 18, 4:17PM CDT
Amgen (NASDAQ:AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. The primary endpoint was the proportion of patients with > 30 percent reduction from baseline in parathyroid hormone (PTH) levels during an Efficacy Assessment Phase (EAP) defined as the period between weeks 20 and 27. These results follow the recent announcement of positive data from a prior placebo-controlled Phase 3 study of AMG 416 which was similar in design and size.
Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 4:10PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a deal with Avion Pharmaceuticals, LLC, under which four Captisol-enabled programs will be developed and commercialized.
Earnings Look Back: Amgen Is Up 7.7% Since Reporting Quarterly Results 2 Weeks Ago (AMGN)
Comtex SmarTrend(R) - Mon Aug 18, 9:32AM CDT
20 days ago, on July 29th, 2014, Amgen (NASDAQ:AMGN) reported its earnings. Analysts, on average, expected earnings of $2.07 per share on sales of $4.9 billion. Amgen actually reported earnings of $2.37 per share on sales of $5.2 billion, beating EPS estimates by $0.30 and beating revenue estimates by $279.7 million. Shares of Amgen have climbed from $123.31 to $132.80, representing a gain of 7.7% since the company reported earnings 20 days ago.
Final Glance: Biotechnology companies
AP - Thu Aug 21, 5:08PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Thu Aug 21, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead Sciences, Amgen, Roche and Biogen
PR Newswire - Thu Aug 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Roche (OTC:RHHBY-Free Report) and Biogen (Nasdaq:BIIB-Free Report).
Lilly psoriasis drug fares well in late-stage test
AP - Thu Aug 21, 7:55AM CDT
INDIANAPOLIS (AP) — Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.
3 Reasons Gilead Science, Inc.’s Stock Could Rise
Brian Orelli, The Motley Fool - Motley Fool - Wed Aug 20, 4:36PM CDT
Gilead Sciences is trading near all-time highs, but there's still potential for the stock price to go even higher. Here are three things that could send shares higher if they come to fruition. Source: Gilead. 1. Sales of Gilead's...
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.
Early Glance: Biotechnology companies
AP - Wed Aug 20, 11:21AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.
Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck
PR Newswire - Wed Aug 20, 8:20AM CDT
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Medtronic, Inc. (NYSE: MDT) and Merck (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5855-100free.
Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk
M2 - Wed Aug 20, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6xznb6/global_hormone) has announced the addition of the "Global Hormone Replacement Therapy Market 2014-2018" report to their offering. Hormone replacement therapy, also known as hormone therapy, is a means of replacing hormones that are no longer being produced by the body. This type of therapy is usually initiated at menopause or may be started while a woman is in the perimenopausal phase, nearing menopause. Hormone replacement therapy replenishes the hormones required by the human body to function by using bio-identical hormones. The therapy contains estrogen and progesterone, and in some cases testosterone, to reduce symptoms of menopause. This replacement therapy may also protect against osteoporosis, reduce the risk of coronary heart disease, and may prevent or delay the onset of Alzheimer's disease. Replacement therapy can also increase the chance of developing more serious health complications such as blood clots, breast cancer, uterine cancer, and bowel cancer. The analysts forecast the Global Hormone Replacement Therapy market will grow at a CAGR of 2.51 percent over the period 2013-2018. The Global Hormone Replacement Therapy market can be divided into three segments: Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, and Thyroid Hormone Replacement Therapy. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Type of Therapy 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Actavis plc - Bayer AG - Merck & Co. Inc. - Novartis AG - Novo Nordisk A/S - Abbott Laboratories Ltd. - Amgen Inc. - ANI Pharmaceuticals Inc. - Hisamitsu Pharmaceutical Co. Inc. - MylanLaboratories Inc. - Orion Corp. - QuatRx Pharmaceuticals Co. - Teva Pharmaceutical Industries Ltd. - TherapeuticsMD Inc. For more information visit http://www.researchandmarkets.com/research/6x...al_hormone
Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 4:25PM CDT
Amgen Inc. (AMGN) announced that AMG 416 has met the primary as well as secondary endpoints in the second phase III registration study.
14.4% Return Seen to Date on SmarTrend Amgen Call (AMGN)
Comtex SmarTrend(R) - Tue Aug 19, 9:42AM CDT
SmarTrend identified an Uptrend for Amgen (NASDAQ:AMGN) on June 2nd, 2014 at $116.45. In approximately 3 months, Amgen has returned 14.41% as of today's recent price of $133.22.
A New Cannabinoid-based Arthritis Therapy in the Making
ACCESSWIRE - Tue Aug 19, 8:50AM CDT
WHITEFISH, MT / August 19, 2014 / Cannabinoids have been the focus of intense clinical research following the legalization of medical cannabis by several U.S. states. While pioneers like British-based GW Pharmaceuticals plc (NASDAQ: GWPH) have been actively studying cannabinoids since the 1990s, many North American companies haven't started major research until recent years with compounds just starting clinical trials.
Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company
PR Newswire - Tue Aug 19, 12:55AM CDT
Gamida Cell, a world leader in stem cell expansion technologies and therapeutic products, announced today that it has signed an investment and option agreement with Novartis Pharma AG ("Novartis"
. According to the agreement, Novartis will invest $35 million in Gamida Cell and in return will receive 15% equity and an option to fully acquire Gamida Cell. The option is exercisable for a limited period of time following achievement of certain milestones connected to the development of NiCord®, anticipated to be met during 2015. Completion of the transaction is subject to customary closing conditions. 3 Reasons Amgen, Inc.'s Stock Could Rise
Sean Williams, The Motley Fool - Motley Fool - Mon Aug 18, 5:13PM CDT
As you can see below, Amgen shareholders have had a great three years, with Amgen's stock having risen by more than 160%. AMGN data by YCharts The company's second-quarter earnings results, released three weeks ago, prove testament...
Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis
PR Newswire - Mon Aug 18, 4:17PM CDT
Amgen (NASDAQ:AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. The primary endpoint was the proportion of patients with > 30 percent reduction from baseline in parathyroid hormone (PTH) levels during an Efficacy Assessment Phase (EAP) defined as the period between weeks 20 and 27. These results follow the recent announcement of positive data from a prior placebo-controlled Phase 3 study of AMG 416 which was similar in design and size.
Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 4:10PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a deal with Avion Pharmaceuticals, LLC, under which four Captisol-enabled programs will be developed and commercialized.
Earnings Look Back: Amgen Is Up 7.7% Since Reporting Quarterly Results 2 Weeks Ago (AMGN)
Comtex SmarTrend(R) - Mon Aug 18, 9:32AM CDT
20 days ago, on July 29th, 2014, Amgen (NASDAQ:AMGN) reported its earnings. Analysts, on average, expected earnings of $2.07 per share on sales of $4.9 billion. Amgen actually reported earnings of $2.37 per share on sales of $5.2 billion, beating EPS estimates by $0.30 and beating revenue estimates by $279.7 million. Shares of Amgen have climbed from $123.31 to $132.80, representing a gain of 7.7% since the company reported earnings 20 days ago.
